Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

Literature DB >> 16363817

Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

Amanda L Harris¹, Xiaohong Yang, Alex Hegmans, Lawrence Povirk, John J Ryan, Lloyd Kelland, Nicholas P Farrell.

Abstract

Charge delocalization (6+ to 8+) in "noncovalent" linear trinuclear platinum complexes produces compounds with cytotoxicity in some cases equivalent to cisplatin. The cellular uptake of a novel 8+ compound is greater than that of neutral cisplatin as well as other multinuclear Pt compounds.

Entities: Chemical Disease

Mesh：

Substances：
Platinum Compounds

Year: 2005 PMID： 16363817 DOI： 10.1021/ic051390z

Source DB: PubMed Journal: Inorg Chem ISSN： 0020-1669 Impact factor: 5.165

Keyword Cloud
Cited

20 in total

1. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

Authors: Christine Billecke; Susan Finniss; Laura Tahash; Cathie Miller; Tom Mikkelsen; Nicholas P Farrell; Oliver Bögler
Journal: Neuro Oncol Date: 2006-05-24 Impact factor: 12.300

2. Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design.

Authors: Eva I Montero; Brad T Benedetti; John B Mangrum; Michael J Oehlsen; Yun Qu; Nicholas P Farrell
Journal: Dalton Trans Date: 2007-10-02 Impact factor: 4.390

3. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

Authors: Ho-Shin Gwak; Takashi Shingu; Vaibhav Chumbalkar; Yeo-Hyeon Hwang; Robert DeJournett; Khatri Latha; Dimpy Koul; W K Alfred Yung; Garth Powis; Nicholas P Farrell; Oliver Bögler
Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396

4. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors: Katherine S Lovejoy; Stephen J Lippard
Journal: Dalton Trans Date: 2009-10-01 Impact factor: 4.390

5. Substitution-inert trinuclear platinum complexes efficiently condense/aggregate nucleic acids and inhibit enzymatic activity.

Authors: Jaroslav Malina; Nicholas P Farrell; Viktor Brabec
Journal: Angew Chem Int Ed Engl Date: 2014-09-24 Impact factor: 15.336

6. New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities.

Authors: Andjela A Franich; Marija D Živković; Tatjana Ilić-Tomić; Ivana S Đorđević; Jasmina Nikodinović-Runić; Aleksandar Pavić; Goran V Janjić; Snežana Rajković
Journal: J Biol Inorg Chem Date: 2020-03-11 Impact factor: 3.358

Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

1. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

2. Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design.

3. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

4. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

5. Substitution-inert trinuclear platinum complexes efficiently condense/aggregate nucleic acids and inhibit enzymatic activity.

6. New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities.

7. Assessing the intracellular fate of rhodium(ii) complexes.

8. Solution studies on DNA interactions of substitution-inert platinum complexes mediated via the phosphate clamp.

9. Peptide targeting of platinum anti-cancer drugs.

10. Molecular dynamics simulation of non-covalent interactions between polynuclear platinum(II) complexes and DNA.